Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Preliminary Results from BCG-Unresponsive NMIBC Treatment

<< Previous

Bullboard Posts

Next >>

Comment by fredgoodwinsonon May 17, 2022 9:32am

129 Views

Post# 34688797

RE:RE:RE:RE:RE:RE:RE:RE:Preliminary Results from BCG-Unresponsive NMIBC Treatment

With the age profile of bladder cancer many could end up being excluded. In the age group from 60 to 79, 70.2% of men and 70.9% of women have some type of cardiovascular disease. By age 80 and above, that increases to 83% of men and 87.1% of women.

Plus up to 23.5 million Americans (more than seven percent of the population) suffer from an autoimmune disease—and the prevalence is rising.

Just need to see some decent numbers for TLD-1433 with the next update.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023